T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into...

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has shown significant success in hematological malignancies.
• Checkpoint inhibitors have demonstrated durable clinical responses in certain solid tumors.
• These successes fuel interest in engineered T-cell therapies for solid tumors.

Purpose of the Study:

• To review clinical data and preclinical advancements in engineered T-cell receptor (TCR) and CAR T-cell therapies for solid tumors.
• To explore strategies for improving T-cell therapy efficacy in the context of solid tumors.

Main Methods:

• Review of published clinical data for TCR and CAR T-cell therapy in solid tumors.
• Analysis of recent preclinical research in T-cell engineering for solid tumors.
• Discussion of key challenges and potential solutions in T-cell therapy development.

Main Results:

• Engineered TCR and CAR T-cell therapies have shown objective clinical responses in select solid tumor types.
• Preclinical models demonstrate promising responses for these advanced T-cell therapies.
• Significant challenges remain, including target selection, T-cell trafficking, and the immunosuppressive tumor microenvironment.

Conclusions:

• Engineered T-cell therapies hold potential for treating solid tumors, building on existing successes.
• Further integration of preclinical findings is crucial to enhance T-cell therapy efficacy against solid tumors.
• Healthcare systems must adapt to facilitate the delivery of these complex treatments.